Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch
US FDA Cleared KRAS G12C Inhibitor For Second-Line NSCLC
Executive Summary
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.
You may also be interested in...
Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price
Krazati was approved for second-line NSCLC with labeling that positions it ahead of Lumakras on efficacy, but not safety. Pricing is slightly higher than for Amgen’s drug.
Amgen’s Lumakras Efficacy Confirmed In Phase III, But Not As Strong As Phase II
Lumakras data at ESMO in KRAS G12C-mutated lung cancer bested docetaxel on PFS, and largely on safety. OS was better for chemotherapy, but the trial was not powered for statistical significance on OS.
Mirati’s Adagrasib Appears To Maintain CRC Edge In KRAS Race
The company is reporting strong ORR, durability and PFS at ESMO in heavily pretreated colorectal cancer, an indication where Amgen’s Lumakras has struggled.